Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 4, 2020
- Accepted in final form September 11, 2020
- First Published November 10, 2020.
Author Disclosures
- Ruth Schneider, MD,
- Barbara Bellenberg, PhD,
- Barbara Gisevius, PhD,
- Sarah Hirschberg, PhD,
- Roman Sankowski, MD,
- Marco Prinz, MD,
- Ralf Gold, MD,
- Carsten Lukas, MD and
- Aiden Haghikia, MD
- Ruth Schneider, MD,
NONE
NONE
(1)Biogen Idec GmBH, (2) Roche Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barbara Bellenberg, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Funding source: German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis KKNMS, grant numbers: 01GI1601I and 01GI0914) Barbara Bellenberg received financial support by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no.01GI1601I.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barbara Gisevius, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah Hirschberg, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roman Sankowski, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Prinz, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD,
(1) TEVA Laquinimod DSMB, AbbVie
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis, Roche
SAGE Journal TAND, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research support from Biogen, Merck and Novartis
NONE
NONE
NONE
From Roche From Merck From Bayer
NONE
NONE
NONE
NONE
NONE
- Carsten Lukas, MD and
1) Scientific advisory board; BiogenIdec, commercial 2) Scientific advisory board; Novartis, commercial 3) Scientific advisory board; Merck, commercial 4) Scientific advisory board; Genzyme, commercial
NONE
1) Travel and speaker honoraria; commercial; Bayer Schering 2) Travel and speaker honoraria; commercial; Novartis 3) Travel and speaker honoraria; commercial; BiogenIdec 4) Travel and speaker honoraria; commercial; Teva 5) Travel and speaker honoraria; commercial; Genzyme 6) Speaker honoraria; commercial; Daiichi Sankyo 7) Travel honoraria; commercial; Stryker
Frontiers Neurology, Applied Neuroimaging; Review Editor, 2017 - no compensation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Federal Ministry of Education and Research of the Federal Republic of Germany (BMBF); 01GI1601I, PI, 3years
NONE
1) Novartis Foundation, endowed Professorship for MS Imaging,
NONE
NONE
NONE
NONE
NONE
NONE
- Aiden Haghikia, MD
NONE
NONE
AH has received speakerÂs fees from Bayer Healthcare, Biogen, Celgene, Genzyme, Merck, Novartis, and Teva
NONE
filed a patent for microRNA Profiling for Diagnosis of MS
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (R. Schneider, B.G., S.H., R.G., A.H.), Institute of Neuroradiology (R. Schneider, B.B., C.L.), and Department of Radiology and Nuclear Medicine (C.L.), St. Josef Hospital, Ruhr University Bochum; Institute of Neuropathology (R. Sankowski, M.P.), Medical Faculty, Signalling Research Centers BIOSS and CIBSS (M.P.), and Center for Basics in NeuroModulation (NeuroModulBasics) (M.P.), Faculty of Medicine, University of Freiburg, Germany.
- Correspondence
Dr. Schneider ruth.schneider{at}rub.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MSSinah Engel, Michaela Friedrich, Muthuraman Muthuraman et al.Neurology: Neuroimmunology & Neuroinflammation, July 19, 2019 -
What's Happening
What's Happening in Neurology® Neuroimmunology & Neuroinflammationet al.Neurology, March 29, 2021 -
Article
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosisEmily Feneberg, Patrick Oeckl, Petra Steinacker et al.Neurology, December 06, 2017 -
Article
Serum neurofilament is associated with progression of brain atrophy and disability in early MSJens Kuhle, Bardia Nourbakhsh, Donna Grant et al.Neurology, February 01, 2017